Quick Answer
Cogent Biosciences, Inc. reported Operating Income of -$333.36 million for fiscal year 2025.
Cogent Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$333.36M | -20.8% |
| 2024 | -$275.94M | -32.6% |
| 2023 | -$208.13M | -40.8% |
| 2022 | -$147.84M | -95.7% |
| 2021 | -$75.55M | +8.1% |
| 2020 | -$82.20M | -155.5% |
| 2019 | -$32.18M | +10.6% |
| 2018 | -$36.01M | -37.7% |
| 2017 | -$26.15M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$83.36M | -10.5% | -10.3% |
| June 30, 2025 | -$75.58M | -17.4% | -0.9% |
| March 31, 2025 | -$74.93M | -20.1% | +0.6% |
| September 30, 2024 | -$75.41M | -26.6% | -17.1% |
| June 30, 2024 | -$64.39M | -36.7% | -3.2% |
| March 31, 2024 | -$62.40M | -44.3% | -4.7% |
| September 30, 2023 | -$59.58M | -61.8% | -26.5% |
| June 30, 2023 | -$47.09M | -31.3% | -8.9% |
- Cogent Biosciences, Inc. showed a decrease of -20.8% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Cogent Biosciences, Inc.’s operating income has declined by 1174.7% (from -$26.15 million to -$333.36 million).
- The most recent figure is from Cogent Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: